We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

1 hedge funds and large institutions have $10K invested in Loncar China BioPharma ETF in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$10.4K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$10K +$10.4K +436 New

CHNA Hedge Fund Activity: Q3 2018 in Review

1 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2018, worth a combined $10K.

Buyers outnumbered sellers: 1 fund opened new CHNA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $10.4K.

  • 1 institutional investor held Loncar China BioPharma ETF (CHNA) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $10K of Loncar China BioPharma ETF stock for Q3 2018.
  • 1 fund opened new Loncar China BioPharma ETF positions in Q3 2018 and 0 closed out, a net change of +1 holder.
  • The largest Loncar China BioPharma ETF buyer in Q3 2018 was UBS Group, an estimated $10.4K added.

Based on aggregated 13F filings for Q3 2018.